#USA #San Diego #Aethlon Medical #North Immunology #NOR-101

Major Merger in Biotech: Aethlon Medical and North Immunology

In a significant move within the biotechnology sector, Aethlon Medical, Inc. has announced its merger with North Immunology. This merger aims to bolster the development of a cutting-edge bispecific antibody known as NOR-101, specifically designed to combat atopic dermatitis by inhibiting both type 2 and type 1 inflammatory pathways.

Overview of the Merger

The merger agreement consists of an all-stock transaction between Aethlon Medical and North Immunology, alongside their respective subsidiaries. This merger is noteworthy as North Immunology has made rapid advancements in creating bispecific antibodies that provide effective treatment options for immune and inflammatory diseases. Their lead product, NOR-101, is particularly promising as it targets two different aspects of inflammation that contribute to atopic dermatitis, a skin condition affecting millions around the globe.

Financial Backing

To support the merger and the advancement of NOR-101, an oversubscribed private placement has generated approximately $180 million. This robust funding is poised to sustain the newly merged company's operations well into the second half of 2028, enabling them to focus on clinical development and potentially market introduction. Prominent institutional investors, including Bain Capital and Janus Henderson Investors, have played a crucial role in this financing effort, highlighting the confidence in the future success of this merger and its products.

Clinical Development Plans

Aethlon Medical and North Immunology have ambitious plans for the clinical development of NOR-101. The Phase 1a clinical trial is set to commence in the first quarter of 2027, with anticipated interim pharmacokinetic and safety results expected by mid-2027. This will be followed by Phase 1b and Phase 2b clinical studies that aim to culminate in 2028. The early data from these trials could be pivotal, not only for the companies involved but also for patients suffering from atopic dermatitis, as they seek effective treatment solutions.

The Vision Behind NOR-101

The goal driving the development of NOR-101 is to provide a 'best-in-disease' therapeutic profile for patients with atopic dermatitis. As noted by Mohit Gupta, Co-Founder and CSO of North Immunology, while current monoclonal antibody therapies for type 2 inflammation have profoundly transformed treatment outcomes, many patients still grapple with significant disease burdens. By simultaneously addressing both type 2 and non-type 2 inflammation pathways, NOR-101 holds the promise of offering a new standard of care.

Leadership and Future Direction

Once the merger finalizes, the combined entity will operate under the name North Immunology, Inc., taking on the Nasdaq symbol NRTX. This transition signifies a commitment to innovation and excellence in the biotechnology landscape. Daniel Schneeberger, co-founder of North Immunology, expressed pride in the progress achieved so far and is enthusiastic about the upcoming clinical trials.

Conclusion

The merger of Aethlon Medical and North Immunology represents a crucial step towards advancing innovative therapies for atopic dermatitis. With strong financial backing, a clear clinical plan, and leadership committed to development, the combined company is well-positioned to impact patients' lives positively. As they move forward into clinical studies, industry observers and investors will be keenly watching this merger's progress and the expected outcomes of NOR-101's trials.